Phase III Clinical Trial: "Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer
The purpose of this study is to determine the efficacy and safety the combination of TRANSKRIP ® vs placebo plus Carboplatin/Paclitaxel as first line treatment in patients with recurrent-persistent cervical cancer.
Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer.
The current standard for recurrent, persistent or metastatic cervical cancer is palliative chemotherapy with cisplatin topotecan, however, the results need to be improved. Epigenetic aberrations play an important role in cancer progression by silencing growth regulatory genes and there is now evidence that inhibitors of DNA methylation and HDAC inhibition synergize the cytotoxicity of chemotherapy.
Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate plus standard cisplatin topotecan against placebo plus cisplatin topotecan upon progression-free survival.
Hypothesis. Hydralazine and magnesium valproate associated to cisplatin topotecan will increase progression-free survival from 4.6 to 7.6 months as compared with the same regimen of chemotherapy plus placebo.
A Phase II Study of Epigenetic Therapy With Hydralazine and Magnesium Valproate to Overcome Chemotherapy Resistance in Refractory Solid Tumors
Chemotherapy resistance, either innate or acquired requires for its development, expression changes on a large number of genes therefore, it has been hypothesized that epigenetic-mediated changes could be the responsible driving force for chemotherapy resistance. Aberrant DNA methylation and histone deacetylation are the main epigenetic alterations hence, their reversal by inhibitors of DNA methylation and histone deacetylases (HDACs) may overcome resistance in refractory solid tumors.
Patients will be treated with hydralazine and magnesium valproate starting from day -7 until chemotherapy ends which consists on the same pre-study protocol regimen on which patients progressed. Response and toxicity were evaluated. Global DNA methylation and HDAC activity were evaluated in the peripheral blood cells, as well as the plasma levels of valproic acid and hydralazine.
100 项与 Psicofarma SA de CV 相关的临床结果
0 项与 Psicofarma SA de CV 相关的专利(医药)
2014-11-01·Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2区 · 医学
Cost-Effectiveness Analysis of Oxycodone Lp An Opioid Analgesic for Patients With Moderate To Severe Pain Secondary To Cancer In Mexico
2区 · 医学
Article
作者: Escobar, Juárez Y ; Fernandez, Z ; Sanchez, K ; Constanzo, A ; Melendez, C ; Soto, Molina H
2014-11-01·Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2区 · 医学
Cost-Minimization Analysis of Methadona Opioid Analgesic for Mexican Patients With Acute and Chronic Secondary Cancer As Rotation Option In Severe Pain
2区 · 医学
Article
作者: Escobar, Juárez Y ; Fernandez, Z ; Sanchez, K ; Melendez, C ; Soto, Molina H ; Constanzo, A
2014-11-01·Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2区 · 医学
Cost-Effectiveness Analysis of Hydralazine and Magnesium Valproate LP Associated With Treatment for Adult Patients with Metastatic Recurrent or Persistent Cervical Cancer in Mexico
2区 · 医学
Article
作者: Escobar, Juárez Y ; Fernandez, Z ; Sanchez, K ; Melendez, C ; Constanzo, A ; Soto, H
100 项与 Psicofarma SA de CV 相关的药物交易
100 项与 Psicofarma SA de CV 相关的转化医学